Thursday,
18 August 2022

Weixel

FDA approves $2.8m gene therapy treatment for rare blood disorder (1)
by Nathaniel Weixel - 08/17/22 5:42 PM ET The Food and Drug Administration (FDA) on Wednesday approved the first gene therapy treatment that could offer a permanent cure for patients who suffer from a rare blood disorder, which the manufacturer priced at $2.8 million per patient. The cost would make the therapy one of the most expensive treatments of all time. The therapy was developed by bluebird bio and will be sold under the brand
In news

Personas

Regions